Oramed Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview
08/08/2025 22:41
Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Oramed Pharmaceuticals Inc is for a loss of 19 cents per share. The mean earnings estimate of analysts was unchanged in the last three months. This summary was machine generated August 8 at 21:41 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Oramed Pharmaceuticals
See all newsBrief: Nano Dimension Appoints Nadav Kidron To Board Of Directors To Chair Strategy And Capital Allocation Committee
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Brief: Oramed And Lifeward Announce Strategic Transaction
Brief: Oramed Receives $18 Million Payment From Scilex Holdings
Brief: Oramed Reports Fiscal Third Quarter 2025 Financial Results